What are the standard first-line treatment options for Ovarian Cancer

First-Line Treatment Options for Ovarian Cancer

Based on the NCCN Guidelines (Version 3.2025), the standard first-line treatment approach for ovarian cancer typically involves surgery followed by chemotherapy, though the specific plan depends on your cancer stage and individual circumstances.

THE TWO-PART APPROACH

Part 1: Surgery (Cytoreductive Surgery)

According to NCCN Guidelines, surgery is the foundation of treatment for most ovarian cancer patients. The goals are to:

• Remove the tumor and affected tissues
• Determine the cancer stage (how far it has spread)
• Remove as much disease as possible

Standard surgical procedures typically include:

• Hysterectomy (removal of the uterus)
• Bilateral salpingo-oophorectomy (BSO) - removal of both ovaries and fallopian tubes
• Omentectomy (removal of the omentum, a tissue in the abdomen)
• Lymphadenectomy (removal of suspicious lymph nodes)

The NCCN Guidelines emphasize that a gynecologic oncologist should perform primary surgery because outcomes are significantly better with this specialized expertise.

Part 2: Chemotherapy (After Surgery)

After surgery, most patients receive platinum-based chemotherapy. According to NCCN Guidelines, the main chemotherapy options include:

Standard IV (Intravenous) Chemotherapy:

• Carboplatin + Paclitaxel (most common)
• This is given through the bloodstream

IV/IP (Intravenous/Intraperitoneal) Combination:

• Chemotherapy delivered both through the bloodstream AND directly into the abdominal cavity
• The NCCN Guidelines note this approach can improve survival but has increased side effects (more myelosuppression, kidney toxicity, abdominal pain, neuropathy, and GI problems)
• Requires careful patient selection and monitoring

IP (Intraperitoneal) Chemotherapy:

• Cisplatin + Paclitaxel delivered directly into the abdomen
• Requires normal kidney function and careful fluid management

TREATMENT VARIES BY STAGE

According to NCCN Guidelines, your specific treatment plan depends on cancer stage:

Stage I Disease (Early-Stage):

• Some patients may be observed without chemotherapy if they have low-risk features
• Others receive standard IV platinum-based chemotherapy
• Observation is an option for select patients with complete surgical staging and certain favorable tumor types

Stage II-IV Disease (Advanced):

• Platinum-based chemotherapy is recommended for nearly all patients
• IV, IV/IP, or IP approaches are options
• Bevacizumab (an anti-angiogenesis drug that cuts off blood supply to tumors) may be added in some cases

MAINTENANCE THERAPY (After Initial Chemotherapy)

This is an increasingly important part of treatment. According to NCCN Guidelines, after completing initial chemotherapy, patients may be eligible for maintenance therapy if they respond well. Options include:

• PARP Inhibitors (olaparib, niraparib, rucaparib) - especially for patients with BRCA mutations or HRD (homologous recombination deficiency)
• Bevacizumab - for patients with wild-type BRCA status
• Observation - for some early-stage patients

IMPORTANT CONSIDERATIONS

Before Treatment Starts: According to NCCN Guidelines, you should discuss:

• Different primary therapy options available to you
• If considering IV/IP chemotherapy, the increased toxicities compared to IV alone
• Your fertility goals (if applicable)
• Clinical trial participation opportunities

During Treatment:

• Regular monitoring with physical exams and blood tests
• CA-125 tumor marker monitoring
• Imaging (CT, MRI, or PET scans) as clinically indicated
• Dose adjustments based on side effects

Molecular Testing: The NCCN Guidelines recommend tumor molecular analysis to identify:

• BRCA1/2 mutations
• HRD (homologous recombination deficiency) status
• Other biomarkers that may guide treatment selection

QUESTIONS TO ASK YOUR ONCOLOGY TEAM

1. What is my cancer stage and histologic type? This determines which treatment options apply to me.
2. Am I a candidate for primary surgery, or would neoadjuvant chemotherapy (before surgery) be better for me?
3. Which chemotherapy approach do you recommend—IV alone, IV/IP combination, or IP? What are the pros and cons for my specific situation?
4. What molecular testing has been done on my tumor? Do I have BRCA mutations or HRD status?
5. What maintenance therapy options might I be eligible for after initial chemotherapy?
6. Are there clinical trials available for my stage and type of ovarian cancer?
7. What side effects should I expect, and how will they be managed?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.